Evidence map›Paper›PMID 39214892›Full record

ArticleEuropean radiology2025

Low dose optimization for total-body 2-[

Taoying Gu, Siwei Liu, Xiaoguang Hou, Liwei Zhao, Yee Ling Ng, Jingyi Wang, Hongcheng Shi

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Total-bodyEJNMMI research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Taoying Gu *Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, 180 Fenglin Road, 200032, Shanghai, People's Republic of China.
Siwei Liu *Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, 180 Fenglin Road, 200032, Shanghai, People's Republic of China.
Xiaoguang HouDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, 180 Fenglin Road, 200032, Shanghai, People's Republic of China.
Liwei ZhaoUnited Imaging Healthcare Co., Ltd., Shanghai, China.
Yee Ling NgUnited Imaging Healthcare Co., Ltd., Shanghai, China.
Jingyi WangUnited Imaging Healthcare Co., Ltd., Shanghai, China.
Hongcheng ShiDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, 180 Fenglin Road, 200032, Shanghai, People's Republic of China. shi.hongcheng@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0003-4813-4262

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesImplementing personalization protocol in clinical routine necessitates diverse low-dose PET/CT scan protocols. This study explores the clinical feasibility of one-third (1/3) dose regimen and evaluates the diagnostic image quality and lesion detectability of BMI-based 1/3-injection doses for 2-[

methodsSeventy-four cancer patients underwent total-body 2-[

resultsSubjective assessments of 1/3-dose and full-dose PET images showed strong agreement among readers (κ > 0.88). In the 1/3-dose group, the Likert scores were above 4. G5, G6, and G8 showed comparable image quality, with G5 demonstrating higher lesion conspicuity than G6 and G8 (p = 0.045). Objective evaluation showed no significant differences in SUV

conclusionA BMI-stratified 1/3-dose regimen is a feasible low-dose alternative with clinically acceptable lesion detectability equivalent to full-dose protocol, potentially expanding the applicability of personalized protocols. CLINICAL RELEVANCE STATEMENT: This study demonstrated that BMI-stratified 1/3-dose regimens for [ KEY POINTS: Currently, limited personalized low-dose total-body PET/CT protocols are available, particularly for patients with varied BMI. Reducing the radiotracer dose to 1/3 the standard demonstrated comparable image quality and lesion detectability equivalent to full dose. BMI-stratified 1/3-dose regimen is a clinically feasible low-dose alternative.

Indexed as

Body Mass IndexFluorodeoxyglucose F18NeoplasmsPositron Emission Tomography Computed TomographyRadiation DosageRadiopharmaceuticalsWhole Body ImagingAdultAgedAged, 80 and overFeasibility StudiesFemaleHumansMaleMiddle AgedProspective StudiesFluorodeoxyglucose F18Radiopharmaceuticals[18F]FDGBody mass indexFeasibility studiesMedical oncologyTotal-body positron emission tomography/computed tomography

Identifiers

PMID39214892

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.